NBT Bank N A NY Has $6.45 Million Position in Pfizer Inc. (NYSE:PFE)

NBT Bank N A NY lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 10.2% in the second quarter, HoldingsChannel reports. The institutional investor owned 230,381 shares of the biopharmaceutical company’s stock after buying an additional 21,319 shares during the period. NBT Bank N A NY’s holdings in Pfizer were worth $6,447,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of PFE. Olistico Wealth LLC acquired a new stake in shares of Pfizer in the 2nd quarter valued at approximately $25,000. MFA Wealth Advisors LLC acquired a new position in shares of Pfizer during the 2nd quarter worth about $29,000. Creekmur Asset Management LLC bought a new position in Pfizer during the fourth quarter worth about $32,000. Trivant Custom Portfolio Group LLC raised its stake in Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares during the period. Finally, Financial Connections Group Inc. bought a new position in shares of Pfizer during the 2nd quarter worth approximately $34,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the subject of several research reports. Wells Fargo & Company lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Barclays lifted their price target on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Trading Up 1.0 %

PFE opened at $29.01 on Friday. The company’s 50 day moving average is $28.99 and its 200-day moving average is $28.01. The company has a market cap of $164.39 billion, a P/E ratio of -483.42, a PEG ratio of 1.02 and a beta of 0.69. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $36.29.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. During the same period last year, the company earned $0.67 earnings per share. The business’s quarterly revenue was up 2.1% on a year-over-year basis. Equities research analysts predict that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be issued a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.79%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.